Immune checkpoint inhibitor (ICI)-based immunotherapy has significantly improved survival outcomes and radically changed the management of many different types of solid tumors, including melanoma. Almost half of advanced melanoma patients achieve a long-term clinical benefit from ICIs. Unfortunately, the other half of treated patients either rapidly progress or achieve a short-term clinical benefit due to the development of resistance. As a result, novel therapeutic strategies are urgently needed to overcome ICI resistance. Epigenetic alterations affecting the tumor neoantigen presentation system or modifying the tumor microenvironment can mitigate ICI resistance. Several studies have demonstrated that epigenetic alterations are potentially targetable by epigenetic modifiers, laying the foundation for the development of novel therapeutic strategies to overcome ICI resistance. In the present work, we summarize the major epigenetic alterations involved in the pathogenesis of melanoma and their role in ICI resistance. Preclinical evidence supporting the biological rationale for combining epigenetic modifiers with ICIs and an updated overview of the main clinical trials testing epigenetic modifiers for the treatment of melanoma patients will be presented.
Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) or its ligand 1 (PD-L1) have revolutionized the management of many types of solid tumors, including metastatic renal cell carcinoma (mRCC). Both sequential and combinatorial therapeutic strategies utilizing anti-PD-1 monoclonal antibodies (mAbs) and anti-angiogenic tyrosine kinase inhibitors (TKIs) have demonstrated to improve the survival of patients with mRCC as compared to standard therapies. On the other hand, both ICIs and TKIs are well known to potentially cause thyroid disorder adverse events (TDAEs). However, in the context of sequential therapeutic strategy, it is not clear whether prior anti-angiogenic TKI may increase the risk and/or the severity of ICI-related TDAEs. In this work, by describing and analyzing a case series of mRCC patients treated sequentially with prior TKIs and then with ICIs, we investigated the role of prior anti-angiogenic TKI-based treatment as a potential predisposing factor to anti-PD-1-mediated recurrent TDAEs, as well as its potential impact on the clinical characteristics of nivolumab-mediated recurrent TDAEs. Fifty mRCC patients were included in the analysis. TKI-mediated TDAEs were reported in ten out of fifty patients. TKI-mediated TDAEs were characterized by hypothyroidism in all ten patients. Specifically, 40%, 40% and 20% of patients presented grade 1, 2 and 3 hypothyroidisms, respectively. Following tumor progression and during anti-PD-1 nivolumab treatment, five out of ten patients developed anti-PD-1 nivolumab-mediated recurrent TDAEs. Anti-PD-1 nivolumab-mediated recurrent TDAEs were characterized by an early transient phase of thyrotoxicosis and a late phase of hypothyroidism in all five patients. The TDAEs were grade 1 and 2 in four and one patients, respectively. Prior anti-angiogenic TKI did not modify the clinical characteristics of nivolumab-mediated recurrent TDAEs. However, all five patients required an increased dosage of levothyroxine replacement therapy. In conclusion, our work suggests that prior anti-angiogenic TKI-based treatment significantly increases the risk of ICI-mediated recurrent TDAEs in patients with mRCC without modifying their clinical characteristics. The most relevant effect for these patients is the need to increase the dosage of lifelong levothyroxine replacement therapy.
Non-small cell lung cancer (NSCLC) is the second most common cancer worldwide, resulting in 1.8 million deaths per year. Most patients are diagnosed with a metastatic disease. Brain metastases are one of the most common metastatic sites and are associated with severe neurological symptoms, shorter survival, and the worst clinical outcomes. Brain radiotherapy and systemic oncological therapies are currently used for controlling both cancer progression and neurological symptoms. Brain radiotherapy includes stereotactic brain ablative radiotherapy (SBRT) or whole brain radiotherapy (WBRT). SBRT is applied for single or multiple (up to ten) small (diameter less than 4 cm) lesions, whereas WBRT is usually applied for multiple (more than ten) and large (diameter greater than 4 cm) brain metastases. In both cases, radiotherapy application may be viewed as an overtreatment which causes severe toxicities without achieving a significant clinical benefit. Thus far, a number of scoring systems to define the potential clinical benefits derived from brain radiotherapy have been proposed. However, most are not well established in clinical practice. In this article, we present a clinical case of a patient with advanced NSCLC carrying a BRAFV600E mutation and brain metastases. We review the variables in addition to applicable scoring systems considered to have potential for predicting clinical outcomes and benefits of brain radiotherapy in patients with advanced NSCLC and brain metastases. Lastly, we highlight the unmet need of specific scoring systems for advanced NSCLC patients with brain metastases carrying oncogene alterations including BRAFV600E mutations.
Background: Thymoma-associated myasthenia gravis (TAMG) occurs in about 30% of patients affected by thymic epithelial tumors (TETs) and leads to a suboptimal response to treatment. Myasthenia gravis (MG) is a chronic autoimmune disease caused by acetylcholine receptor (AChR) generally and other autoantibodies reacting against the neuromuscular junction. The complement system plays an important role in the pathogenesis of MG. AChR antibodies [immunoglobulin G (IgG) oligomers] in MG can activate the complement cascade binding C1q; consequently, complement inhibitors, such as eculizumab, are now available for treatment in MG refractory to standard treatment. Before starting treatment with complement inhibitors, it is mandatory to be vaccinated against Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae type B. Limited data are available regarding TAMG: the most significant study is a real-world cohort presented by Lei Jin, and sporadic case reports. In the phase III, randomized, double-blind, placebo-controlled REGAIN study patients with a history of thymoma or thymic neoplasm were excluded. Conversely, Lei Jin’s study involving eculizumab included 42 seropositive AChR antibodies patients with refractory MG, but only 22 patients were included. Two patients reported coronavirus disease 19 (COVID-19) and herpes labialis infection, while four patients died from respiratory or circulatory failure linked to thymoma metastasis. Case Description: We reported our experience with a young patient who underwent thymectomy diagnosed with stage IV thymoma type B2, with lung and pleural metastasis (pT3 pNx M1a) and a higher frequency of myasthenic crisis. Cisplatin, adriamycin and cyclophosphamide (PAC schedule) were administered for six cycles. Good’s syndrome (GS) was diagnosed based on low levels of B lymphocytes and Immunoglobulins. MG was treated with corticosteroids, pyridostigmine, immunoglobulins and plasmapheresis. The patient was included in an experimental protocol involving complement inhibitors for the treatment of refractory MG. After two months from the initiation of treatment, the patient experienced severe lung infections with exacerbation of myasthenic symptoms and subsequently died. Conclusions: Further studies are needed in patients with myasthenia and TETs with associated immunopathies, particularly GS. Antibacterial prophylaxis, vaccinations, monitoring of C-reactive protein, white blood cell count, immunoglobulins and the diagnosis of refractory MG are mandatory prior to starting treatment with complement inhibitors.
Non-small-cell lung cancer (NSCLC) is the second most common cancer worldwide, resulting in 1.8 million deaths/year. Most of the patients are diagnosed with a metastatic disease. Central Nervous System is one of the major metastatic sites. Brain metastases are associated with severe neurological symptoms, shorter survival and worst clinical outcomes. Brain radiotherapy and systemic oncological therapies are currently used for controlling both cancer progression and neurological symptoms. Brain radiotherapy includes stereotactic brain ablative radiotherapy (SBRT) or whole brain radiotherapy (WBRT). SBRT is applied for single or multiple (≤ 4) small lesions (< 3 cm), while WBRT represents the best treatment choice in case of multiple and large brain metastases. In both cases radiotherapy application can represent an overtreatment causing severe toxicities without achieving a significant clinical benefit. So far, some scores have been proposed to define the potential clinical benefits derived from brain radiotherapy. However, most of them are not well validated into clinical practice. In this article, by presenting a clinical case of a patient with advanced NSCLC carrying a BRAFV600E mutation and brain metastases, we review the variables as well as the potential applicable scores to be considered in order to predict clinical outcomes and benefits from brain radiotherapy in patients with NSCLC and brain metastases.